RSV NewCo

Industry: Treatment for Respiratory Syncytial Virus

RSV NewCo is developing a safe, effective treatment for Respiratory Syncytial Virus (RVS), one of the leading causes of virus-related death for infants, particularly premature infants. Elderly people are also at risk from RSV.
 
There are currently no effective antiviral treatments for RSV, but RSV NewCo is working to identify new antiviral compounds that could effectively treat and prevent RSV in high-risk infants and the elderly. So far, the company has identified a ribonucleoside that provides a strong starting point for a therapeutic. 

Back to companies

191 Peachtree Street, NE, Suite 849  |  Atlanta, Georgia 30303  |  404.332.9770  |  Directions  |  Privacy  |  GRA Venture Fund, LLC
Copyright © Georgia Research Alliance  |  All Rights Reserved